Daily Archives: February 20, 2022

Telemedicine use has increased during the COVID-19 pandemic, but uptake among patient populations has not been equitable. Lack of access to technology or broadband connection contributes to the digital divide, but additional factors at the provider-lev… Continue reading →

SET and MYND domain-containing protein 5 (SMYD5) is a lysine methyltransferase and broadly expressed across various tissues, including immune cells. However, the myeloid SMYD5 in inflammatory bowel disease is entirely unknown. Here, we interrogated the… Continue reading →

Pediatric inflammatory bowel disease (IBD) is commonly treated with infliximab in a hospital setting or clinic where infusions are safely and effectively administered. In recent years, utilization of home infusions (HI) has increased due to reduced cos… Continue reading →

Recent studies have documented the complexity of the intestinal fungal community (‘mycobiome’) in mice, and clinical and experimental observations have shown that the mycobiome influences both gut health and disease, e.g., inflammatory bowel disease (I… Continue reading →

T helper 17 (Th17) cells play a key role in barrier protection in the gastrointestinal tract but are also key pathological drivers of Inflammatory Bowel Disease (IBD). Although a number of key transcription factors governing Th17 differentiation have b… Continue reading →

For patients with medically refractory ulcerative colitis (UC), total proctocolectomy and ileal pouch-anal anastomosis (IPAA) has been the definitive surgery of choice. Approximately 10% of patients who were initially diagnosed with UC and underwent an… Continue reading →

There is a need for novel treatments for patients with inflammatory bowel disease (IBD) who do not respond to medical therapy. It is likely that IBD arises from dysfunctional interactions between the mucosal immune system and the gut microbiome, and ma… Continue reading →

Significant proportion of inflammatory bowel disease (IBD) patients continue to respond inconsistently to therapies, underscoring disease complexity and the need for efficacious treatment. Interleukin 21 (IL-21), which is known to support T helper (Th)… Continue reading →

Post-operative recurrence (POR) after ileocecal resection (ICR) affects most of Crohn’s disease (CD) patients within 3-5 years after surgery. Current immunomodulatory treatments have not proven efficiency in preventing POR, except for anti-TNFα biologi… Continue reading →

Human gastrointestinal (GI) organoid technologies have transformed GI disease research. By recapitulating the essential steps that occur during embryonic organ development, we could generate in vitro human colonic organoids (HCOs) (Munera et al, Cell S… Continue reading →